Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 May 8;17:6. doi: 10.1186/s12895-017-0057-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 1 — Patients using adalimumab, etanercept or ustekinumab will be randomized to dose tapering or usual care. Control visits will be planned every 3 months for the assessments of PASI, DLQI, cost-effectiveness questionnaires, drug levels and anti-drug antibodies (at trough moment). Ustekinumab blood samples for immunologic analyses are taken at deviating time points (trough moments) due to the low frequency of injections. CEQ = Cost-effectiveness questionnaires (SF-36, iMTA Medical Consumption Questionnaire and productivity cost questionnaire), PASI = Psoriasis Area and Severity Index, DLQI = Dermatology Quality of Life